Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 3

2(25.0%)

Phase 1

1(12.5%)

8Total

Phase 2(5)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06443944Unknown

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Role: lead

NCT06567743Phase 2Recruiting

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Role: lead

NCT02143804Phase 2Withdrawn

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

Role: lead

NCT04452591Phase 3Active Not Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Role: lead

NCT04610671Phase 1Completed

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Role: collaborator

NCT06111235Phase 3Active Not Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Role: lead

NCT04387461Phase 2Completed

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Role: lead

NCT02365818Phase 2Completed

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

Role: lead

NCT01438112Phase 2Terminated

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

Role: lead

All 9 trials loaded